Azole Antifungal

PreclinicalSmall molecule

Azole Antifungal is one of 7 small molecule programs targeting Vulvovaginal Candidiasis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Vulvovaginal CandidiasisActive, not recruiting

Vulvovaginal CandidiasisPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Vulvovaginal Candidiasis

#DrugCompanyPhaseTrials

Lotrimin

Bayer

Approved

4 2

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

15 3

Nizoral

Terazol 3

2 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Azole Antifungal

AAssiut University

Preclinical

1 7

Oteseconazole (VT-1161)

MMycovia Pharmaceuticals Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Resistance1 trial

Efflux Pump Mediated Azole Resistance in Candida Albicans

Unknown status·—··NCT03659162·100 enrolled

Vulvovaginal Candidiasis1 trial

Blue Light Emitting Diode Therapy on Vulvovaginal Candidiasis

Completed·—·N/A·NCT05795491·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Azole Antifungal. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Azole Antifungal compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Azole Antifungal. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assiut University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAssiut University

Azole Antifungal

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Resistance1 trial

Vulvovaginal Candidiasis1 trial

References

Drug Info

Quick Facts

Related News